Curis ( CRIS)Drug: GDC-0449 Abstract No. 3530 Indication: colorectal cancer Clinical Trial: Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 vs. placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC). Presentation Time: Tuesday, June 8. Poster session. Notes:GDC-0449 is partnered with Roche/Genentech.
More on Biotech
|14 Biotech Stocks Facing FDA Approval |